New data from Karuna Therapeutics on the schizophrenia treatment KarXT sent shares of the biotech up more than 60% as analysts said the results were strong enough that the drug could be the go-to treatment once it is approved.
Investors were expecting a difference of 7 or 8 points between the study group and people who took a placebo in reduction of schizophrenia symptoms, as measured by a tool known as the Positive and Negative Syndrome Scale, according to a note out Monday by Mizuho analyst Uy Ear.
https://www.barrons.com/articles/karuna-stock-schizophrenia-trial-51659973608?siteid=yhoof2
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.